To Reduce Breast Cancer Recurrence Risk, Exercise—a Lot!

TON - September 2016, Vol 9, No 5 - Breast Cancer
Caroline Helwick

New Orleans, LA—For protection against breast cancer recurrence, results from one recently reported study can best be described as “good news, bad news.”

At the American Association for Cancer Research Annual Meeting 2016, researchers reported a significant response for the effects of physical activity on breast cancer recurrence. The catch is that the effect was seen only among the most active tertile: women who exercised ≥20 hours a week.

Teresa Lehman, PhD, Chief Technology Officer, BioServe Technologies, Ltd, Beltsville, MD, presented the study of 2435 patients surveyed, and 215 who developed a breast cancer recurrence.

“There is reasonable evidence that increased physical activity is associated with a reduced risk of breast cancer, but its role in the recurrence of breast cancer has not been established,” Dr Lehman said.

The study was a secondary analysis of data from the Global Epidemiological Study, a multinational biorepository and database to assess cancer and other disease risk factors and biomarkers.

Patients provided their personal history, including age, body mass index, and information on diet and physical activity. The study examined the association between physical activity and breast cancer recurrence.

Although the sample size was “relatively small,” Dr Lehman acknowledged, a significant effect was observed.

Substantial Reduction in Recurrences

“On the univariate analysis, physical activity had a significant impact on recurrence, and on the multivariate analysis, after adjusting for age, body mass index, and cancer stage, the effect was even greater,” she said in an interview with The Oncology Nurse-APN/PA.

Subjects in the highest tertile of physical activity, who reported brisk walking and other moderate exercise for ≥20 hours a week, were 39% less likely to have a breast cancer recurrence than women reporting no exercise (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.40-0.93); on the multivariate analysis, they were 45% less likely (OR, 0.55; 95% CI, 0.34-0.89). The dose-response relationship was significant (P = .05), Dr Lehman reported.

Patients in the second tertile, who exercised 1 to 20 hours a week, actually had no reduction in recurrence risk (OR, 1.13 on the univariate analysis, and 1.24 on the multivariate analysis). In the first tertile, the reference group, women reported no brisk exercise.

Dr Lehman acknowledged that 20 hours of exercise is a challenge for most women. “You have to really make an effort to do this,” she said.

Source: Lehman TA, Modali RV, Ratnasinghe LD. Recurrent breast cancer risk and physical activity. Abstract 3426.

Related Items
Omega-3 Fatty Acids Significantly Reduced Pain in Obese Patients with Breast Cancer
Meg Barbor, MPH
TON - November 2018, Vol 11, No 5 published on November 28, 2018 in Breast Cancer
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Breast Cancer
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Breast Cancer
Explaining Treatment Regimens to Patients with HR+/HER2- Metastatic Breast Cancer
Thomas Bachelot, MD, PhD
Video Library published on July 19, 2018 in Breast Cancer, Video
HR+/HER2- Metastatic Breast Cancer: Common Presenting Symptoms
Hope S. Rugo, MD
Video Library published on July 19, 2018 in Breast Cancer, Video
Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer
Rebecca Bailey
TON - May 2018, Vol 11, No 2 published on May 15, 2018 in Breast Cancer, Immunotherapy
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
TON Web Exclusives published on April 7, 2018 in Breast Cancer, Online Only, In the News
Taselisib, a PI3K Inhibitor, Shrinks Tumors in Early Breast Cancer, with Added Activity in Patients with PI3KCA Mutation
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Breast Cancer, Drug Updates & News, ESMO
Last modified: September 14, 2016